Microarray-Assisted Pathway Analysis Identifies MT1X & NFκB as Mediators of TCRP1-Associated Resistance to Cisplatin in Oral Squamous Cell Carcinoma

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Peng, Bo ^a,b,c   Gu, Yixue ^a,c   Xiong, Yan ^a   Zheng, Guopei ^a,c   He, Zhimin ^a,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METALLOTHIONEIN I; METALLOTHIONEIN IX; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE B; SMALL INTERFERING RNA; TONGUE CANCER RESISTANCE ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; MOUTH SQUAMOUS CELL CARCINOMA; MT1X GENE; NFKAPPAB GENE; NUCLEOTIDE SEQUENCE; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TCRP1 GENE; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; METALLOTHIONEIN; MOUTH NEOPLASMS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84870886833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051413     Document Type: Article

References (37)

1. Pignon JP, Bourhis J, Domenge C, Designe L, (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955.
2. Haddad RI, Shin DM, (2008) Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154.
3. Kim MJ, Lee JH, Kim YK, Myoung H, Yun PY, (2007) The role of tamoxifen in combination with cisplatin on oral squamous cell carcinoma cell lines. Cancer Lett 245: 284-292.
4. Marsh S, McLeod H, Dolan E, Shukla SJ, Rabik CA, et al. (2009) Platinum pathway. Pharmacogenet Genomics 19: 563-564.
5. Zheng G, Zhou M, Ou X, Peng B, Yu Y, et al. (2010) Identification of carbonic anhydrase 9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells. FEBS J 277: 4506-4518.
6. Gu Y, Fan S, Xiong Y, Peng B, Zheng G, et al. (2011) Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett 585: 881-887.
7. Peng B, Yi S, Gu Y, Zheng G, He Z (2012) Purification and biochemical characterization of a novel protein-tongue cancer chemotherapy resistance-associated protein1 (TCRP1). Protein Expr Purif.
8. Gu Y, Fan S, Liu B, Zheng G, Yu Y, et al. (2011) TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem 357: 107-113.
9. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, et al. (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284.
10. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, et al. (2006) Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5: 433-443.
11. Yamano Y, Uzawa K, Saito K, Nakashima D, Kasamatsu A, et al. (2010) Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer 126: 437-449.
12. Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, et al. (2006) Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 6: 224.
13. Jordan P, Carmo-Fonseca M, (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57: 1229-1235.
14. Lee J, Kang M, Jang S, Qian T, Kim H, et al. (2008) Id-1 activates Akt-mediated Wnt signaling and p27Kip1 phosphorylation through PTEN inhibition. Oncogene 28: 824-831.
15. Morgensztern D, McLeod HL, (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-cancer drugs 16: 797.
16. Kim HG, Hwang YP, Han EH, Choi CY, Yeo CY, et al. (2009) Metallothionein-III provides neuronal protection through activation of Nuclear Factor-κB via the TrkA/Phosphatidylinositol-3 kinase/Akt signaling pathway. Toxicological Sciences 112: 435-449.
17. Gonzalez VM, Fuertes MA, Alonso C, Perez JM, (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663.
18. Kartalou M, Essigmann JM, (2001) Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43.
19. Satoh M, Cherian MG, Imura N, Shimizu H, (1994) Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 54: 5255-5257.
20. Chu G, (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. Journal of Biological Chemistry 269: 787-790.
21. Aydemir TB, Blanchard RK, Cousins RJ, (2006) Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proceedings of the National Academy of Sciences of the United States of America 103: 1699-1704.
22. Winge DR, (1991) [52] Limited proteolysis of metallothioneins. Methods in enzymology 205: 438-447.
23. Chun JH, Kim HK, Kim E, Kim IH, Kim JH, et al. (2004) Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res 64: 4703-4706.
24. Yang F, Zhou M, He Z, Liu X, Sun L, et al. (2007) High-yield expression in Escherichia coli of soluble human MT2A with native functions. Protein Expr Purif 53: 186-194.
25. Kim MO, Moon DO, Heo MS, Lee JD, Jung JH, et al. (2008) Pectenotoxin-2 abolishes constitutively activated NF-kappaB, leading to suppression of NF-kappaB related gene products and potentiation of apoptosis. Cancer Lett 271: 25-33.
26. Moynagh PN, (2005) The NF-kappaB pathway. J Cell Sci 118: 4589-4592.
27. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, et al. (2003) p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63: 7081-7088.
28. Chock KL, Allison JM, Shimizu Y, ElShamy WM, (2010) BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 70: 8782-8791.
29. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, et al. (2000) Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85: 777-781.
30. Hebbring SJ, Moyer AM, Weinshilboum RM, (2008) Sulfotransferase gene copy number variation: pharmacogenetics and function. Cytogenet Genome Res 123: 205-210.
31. Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, et al. (2005) Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11: 7398-7404.
32. Vernhet L, Allain N, Le Vee M, Morel F, Guillouzo A, et al. (2003) Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J Pharmacol Exp Ther 304: 145-155.
33. Konkimalla VB, Kaina B, Efferth T, (2008) Role of transporter genes in cisplatin resistance. In Vivo 22: 279-283.
34. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, et al. (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64: 4294-4301.
35. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P, (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276: 46400-46407.
36. Montpetit A, Cote S, Brustein E, Drouin CA, Lapointe L, et al. (2008) Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord. PLoS Genet 4: e1000296.
37. Zheng G, Xiong Y, Yi S, Zhang W, Peng B, et al. (2012) 14-3-3sigma regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. FEBS Lett 586: 163-168.